Evidence map›Paper›PMID 40137296›Full record

ArticleMarine drugs2025

Fucosylated Glycosaminoglycan Oligosaccharide HS14, Derived from Sea Cucumbers, Is a Novel Inhibitor of Platelet Toll-like Receptor 2.

Huifang Sun, Guangyu Zhu, Sujuan Li, Pengfei Li, Jiali Zhang, Ronghua Yin, Lin Yuan, Na Gao, Jinhua Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Multidimensional mechanisms of SFTSV-host interactions: viral protein functions, mFrontiers in cellular and infection microbiology · 2026
    Review
  3. Dihydrogeodin fromMarine drugs · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Huifang SunSchool of Chemistry and Materials Science, South-Central Minzu University, Wuhan 430074, China.
Guangyu ZhuCollege of Life Sciences, South-Central Minzu University, Wuhan 430074, China.
Sujuan LiState Key Laboratory of Phytochemistry and Plant Resources in West China, Kunming Institute of Botany, Chinese Academy of Sciences, Kunming 650201, China.
Pengfei LiSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.
Jiali ZhangSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.
Ronghua YinSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.
Lin YuanSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.
Na GaoSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.
Jinhua ZhaoSchool of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, China.

Funding

the Fundamental Research Funds for the Central Universities, South-Central Minzu University CZP22002the National Natural Science Foundation of China 82073725, 32471337 and 31900926
6 · The paper itself

Abstract

(1) Background: Toll-like receptor 2 (TLR2) on platelets is increasingly recognized as a pivotal mediator in infection-induced platelet activation and aggregation, contributing to both inflammatory and thrombotic diseases. Targeting TLR2 on platelets offers a promising therapeutic strategy for inflammatory and thrombotic-related disorders. However, inhibitors targeting platelet TLR2 have not yet been reported. (2) Methods: Platelet aggregation was assessed using a light transmission aggregometer. Platelet activation was evaluated by measuring the release of P-selectin and von Willebrand factor (vWF) via ELISA. Intracellular Ca

Indexed as

Blood PlateletsGlycosaminoglycansOligosaccharidesPlatelet Aggregation InhibitorsToll-Like Receptor 2AnimalsCalciumHumansLipopeptidesPlatelet ActivationPlatelet AdhesivenessPlatelet AggregationP-SelectinCalciumGlycosaminoglycansLipopeptidesOligosaccharidesPlatelet Aggregation InhibitorsP-SelectinTLR2 protein, humanToll-Like Receptor 2fucosylated glycosaminoglycaninflammatory diseasesplatelet activationplatelet aggregationplatelet–granulocyte aggregatestoll-like receptor 2

Identifiers

PMID40137296
PMCPMC11943722

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.